Oral News and Research

RSS

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Alvine Pharmaceuticals, Inc. today announced the presentation of data from a Phase 2A trial of its lead compound, ALV003, at the 2012 Digestive Diseases Week (DDW) meeting held in San Diego, California. The study results met the primary endpoint of demonstrating that oral ALV003, administered in the context of a gluten free diet (GFD), can diminish gluten-induced intestinal mucosal injury in well-controlled celiac disease patients. The company plans to initiate a Phase 2B trial later this year.

23 May 2012

$Bisphosphonate therapy may increase risk of atypical femoral fractures$

Bisphosphonate therapy may increase risk of atypical femoral fractures

Treatment with bisphosphonate therapy appears to be associated with an increased risk of atypical fractures of the femur, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

22 May 2012

Noninvasive test can reduce feeding-related complications among premature infants

Tufts Medical Center researchers have shown that presence of a gene strongly linked to appetite regulation is highly predictive of a premature infant's readiness to feed orally. An analysis of just a drop of an infant's saliva could be the key to preventing many feeding problems and the expensive medical complications that can occur when infants are fed by mouth too early.

22 May 2012

FSU announces availability of Pacifier Activated Lullaby device

Many premature babies enter the world with a mountain of challenges in front of them. Even after they overcome any life-threatening issues, they face ongoing, and typically unpleasant, medical procedures, long hospital stays and increased chances of chronic health issues throughout their lives.

22 May 2012

AAPA honors Connecticut physician assistant with Outstanding PA of the Year Award

Since the early days of her career as a physician assistant in family practice, Cynthia Lord, MHS, PA-C, of Cheshire, Conn. has been driven by her passion for serving patients with the greatest need for care. Now, in her position as clinical associate professor at Quinnipiac University's PA program, Lord transfers her empathy for patients and her love of serving others in need to the next generation of PAs.

21 May 2012

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

Vaccination studies from Mercer University (Ga.) headline the groundbreaking research being unveiled at the American Association of Pharmaceutical Scientists' (AAPS) National Biotechnology Conference.

21 May 2012

Auranofin effective against amoebas in lab and animal studies

A team of researchers from UCSF and UC San Diego has identified an approved arthritis drug that is effective against amoebas in lab and animal studies, suggesting it could offer a low-dose, low cost treatment for the amoebic infections that cause human dysentery throughout the world.

21 May 2012

Specific risk factors linked with exacerbation-prone phenotype of severe asthma

A number of specific risk factors are associated with an exacerbation-prone phenotype of severe asthma, according to a new study from researchers in Sweden.

21 May 2012

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Receptos Inc. today announced that company personnel will deliver a scientific podium presentation about RPC1063 at the Digestive Disease Week (DDW) annual meeting at 9 a.m. PDT on Sunday, May 20, 2012 at the San Diego Convention Center in San Diego, California. DDW attracts thousands of physicians, researchers, and academics from around the world to share the latest research in gastrointestinal health topics, for which DDW is the premier scientific conference.

19 May 2012

Studies show vitamin D may benefit cardiovascular, skin and metabolic disorders

The Endocrine Society's new scientific statement published online today represents the first comprehensive evaluation of both the basic and clinical evidence related to the non-skeletal effects of vitamin D. The statement addresses current research regarding the associations of vitamin D with immune function, hypertension, stroke, skin conditions and maternal/fetal health.

19 May 2012

Ocera’s Zysa receives CE Mark to treat IBS-d

Ocera Therapeutics Inc., a privately-held biopharmaceutical company focused on the development and commercialization of proprietary agents to treat gastrointestinal and liver diseases, announced today that it has received a CE Mark for Zysa (spherical carbon adsorbent, formerly AST-120) for the treatment of diarrhea predominant IBS (IBS-d), a condition affecting 10-15% of the Western world.

19 May 2012

IAS’ XIX International AIDS Conference to take place in Washington D.C.

This summer, more than 25,000 leading scientists, public health experts, policy-makers, community members, and experts in the HIV/AIDS field from around the world will gather in our nation's capital for the International AIDS Society's XIX International AIDS Conference.

19 May 2012

Sigmoid provides financial and product development update

Sigmoid Pharma Ltd., a privately-owned, specialty pharmaceutical and drug delivery company registered in Ireland, today provides an update on significant progress in 2011 and 2012.

19 May 2012

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

ArQule, Inc. and Daiichi Sankyo, Co., Ltd. today announced that an oral presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO) will feature Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC).

18 May 2012

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

18 May 2012

Pharmacyclics announces clinical abstracts on ibrutinib to be presented at ASCO annual meeting

Pharmacyclics, Inc. today announced that clinical abstracts on Bruton's Tyrosine Kinase inhibitor, ibrutinib have been selected for oral presentations at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1-5, 2012 in Chicago, IL.

18 May 2012

Dabrafenib drug shrinks tumors in patients with melanoma brain metastases

An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of The Lancet.

18 May 2012

Additional data from Tokai’s galeterone Phase 1 study on CRPC

Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced that additional data from a Phase 1 safety and proof-of-concept study evaluating lead candidate, galeterone, in patients with castration-resistant prostate cancer (CRPC) will be highlighted in a poster presentation titled, "Phase I clinical trial of galeterone, a multifunctional anti-androgen and CYP17 inhibitor in castration resistant prostate cancer," abstract number 4665, on Sunday, June 3, 2012, 8:00 a.m. to 12:00 p.m. at the 2012 Annual Meeting of the American Society of Clinical Oncology.

18 May 2012

Blood platelet concentrates improve healing after dental implant procedures

Restoring the front teeth after a traumatic injury poses a particular challenge—biologically, functionally, and aesthetically. Even when all the procedures of a successful implant are followed, healing of tissues can still be an unpredictable element. One approach to improving the outcome of this type of implant is the use of blood platelet concentrates.

17 May 2012

Cardiac ischemia plays an important role in adenovector gene transfection in mammalian hearts

Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA.

17 May 2012

Oral News and Research

Data from Alvine’s ALV003 Phase 2A trial on celiac disease presented at DDW 2012

Bisphosphonate therapy may increase risk of atypical femoral fractures

Noninvasive test can reduce feeding-related complications among premature infants

FSU announces availability of Pacifier Activated Lullaby device

AAPA honors Connecticut physician assistant with Outstanding PA of the Year Award

Vaccination studies from Mercer University to be unveiled at AAPS’ NBC

Auranofin effective against amoebas in lab and animal studies

Specific risk factors linked with exacerbation-prone phenotype of severe asthma

Receptos to present scientific podium presentation about RPC1063 at DDW 2012

Studies show vitamin D may benefit cardiovascular, skin and metabolic disorders

Ocera’s Zysa receives CE Mark to treat IBS-d

IAS’ XIX International AIDS Conference to take place in Washington D.C.

Sigmoid provides financial and product development update

ArQule to present positive tivantinib Phase 2 clinical data for hepatocellular carcinoma

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

Pharmacyclics announces clinical abstracts on ibrutinib to be presented at ASCO annual meeting

Dabrafenib drug shrinks tumors in patients with melanoma brain metastases

Additional data from Tokai’s galeterone Phase 1 study on CRPC

Blood platelet concentrates improve healing after dental implant procedures

Cardiac ischemia plays an important role in adenovector gene transfection in mammalian hearts

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

Latest News